About i2O Therapeutics
i2O Therapeutics is a private company based in Cambridge, Massachusetts, incorporated in 2019 in Delaware. It has reported $43,939,921 raised in six offerings on Form D since July 2019. Its chief executive is Kurt Graves.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2023 | Oct 18, 2023 | $3,500,000of $3.9M target | 7 | $500K | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jul 18, 2022 | Oct 11, 2022 | $33,539,921of $42.0M target | 17 | $1.9M | EquityRule 506(b) | Form D ↗ |
| Oct 1, 2021 | Jan 24, 2022 | $2,300,000of $3.0M target | 7 | $328K | DebtRule 506(b) | Form D ↗ |
| Nov 16, 2020 | Dec 1, 2020 | $600,000fully sold | 2 | $300K | DebtRule 506(b) | Form D ↗ |
| Mar 13, 2020 | Mar 23, 2020 | $3,200,000fully sold | 2 | $1.6M | DebtRule 506(b) | Form D ↗ |
| Jun 27, 2019 | Jul 11, 2019 | $800,000of $4.0M target | 2 | $400K | DebtRule 506(b) | Form D ↗ |
| Total, six offerings | $43,939,921 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on i2O Therapeutics's Form D filed Oct 18, 2023.
Earlier filings also listed Samir Mitragotri (executive officer and director, last listed Oct 2022), Ravi Srinivasan (president and director, last listed Oct 2022), Katie Ellias (director, last listed Jan 2022) and Mitragotri Mitragotri (executive officer and director, last listed Jul 2019).